C vs TSHA · P/E 16, rev $85.22B vs rev $8.3M
Citigroup Inc. (C) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported TSHA revenue for 2024-12-31 was $8.3M. Net income was -$89.3M. Revenue was down 46.1% from 2023-12-31 to 2024-12-31. TSHA currently screens at market cap $640.7M.
C currently screens at market cap $214.73B and trailing P/E 15.5. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the C and TSHA stock pages for the full models.
Not investment advice.